65,437 trials
Healthy
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Lebrikizumab — 38.5; 41.9 micrograms per milliliter (µg/mL)
Advanced Solid Tumor
Primary: Period 1: Percent Urinary Recovery (Feurine) of Total Radioactivity — 15.8 percentage of administered dose (%)
Smoking Cessation
Primary: End of Treatment Abstinence Rates — 3; 0 Participants
Primary Aldosteronism
Primary: Change in Aldosterone-to-renin Ratio — -15.0; -7.0; -14.0; -11.8 ng*L/dL*mU — p=<0.0001
Venous Thromboembolism
Primary: Number of Participants Who Continued Treatment With Apixaban or Warfarin Following Discharge From the Hospital — 11966; 1979 Participants
E-cigarette Use
Primary: Plasma Nicotine Concentration — 0.78; 1.08; 0.89; 1.16 ng/ml
Oligodendroglioma · Oligoastrocytoma
Primary: Progression-free Survival (PFS) at Six Months (PFS6m) — 21 Percentage of participants
Peripheral Arterial Disease · Peripheral Artery Disease
Primary: Brachial Artery Endothelial Function — 4.34; 4.31; 5.6; 4.35 % dilation
Patient Care Team
Primary: Team Performance Observation Tool — 53.00; 39.00; 39.25; 57.75 score on a scale — p=<0.05
Lung Diseases, Interstitial
Primary: Time to Oxygen Therapy Initiation — 27.5; NA Months
Skeletal Muscle Protein Synthesis
Primary: Change in Acute Muscle Protein Synthesis — 143; 123 percent change
Non-Hodgkin Lymphoma
Primary: Percentage of Participants With Administration-Associated Reactions (AARs) — 1.1; 3.7; 1.6; 1.1 Percentage of Participants %
Metabolic Syndrome
Primary: Waist Circumference (WC) — 98.9; 102.1 cm
Non-small Cell Lung Cancer
Primary: Percentage of Participants Who Preferred Atezolizumab SC to Atezolizumab IV Assessed Using Patient Preference Questionnaire (PPQ) — 71.67; 69.84; 70.73 percentage of…
Postoperative Wound Haemorrhage
Primary: Frequency of Postoperative Hemorrhagic Complications — 0; 6 Participants — p=.028